Skip to main content
SpringerLink
Log in
Book cover

Oral Antidiabetics

  • Book
  • © 1996

Overview

Editors:
  1. Jochen Kuhlmann

    1. Institut für Klinische Pharmakologie, Bayer AG, Wuppertal, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Walter Puls

    1. Wuppertal, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 119)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (24 chapters)

  1. Front Matter

    Pages I-XXXI
    Download chapter PDF

  2. Introduction

    1. Introduction

      • J. Kuhlmann
      Pages 1-5

  3. Pathophysiology of Type 2 Diabetes Mellitus

    1. Pathophysiology of Type 2 Diabetes Mellitus

      • A. J. Scheen, P. J. Lefèbvre
      Pages 7-42

  4. Non-Pharmacological Management of Non-Insulin-Dependent Diabetes

    1. Non-Pharmacological Management of Non-Insulin-Dependent Diabetes

      • J. Köbberling
      Pages 43-62

  5. Sulfonylureas

    1. Front Matter

      Pages 63-63
      Download chapter PDF

    2. Sulfonylureas and Related Compounds: Chemistry and Structure-Activity Relationships

      • H. Plümpe
      Pages 65-72

    3. Sulfonylureas: Physico-chemical Properties, Analytical Methods of Determination and Bioavailability

      • S. L. Ali, H. H. Blume, B. S. Schug
      Pages 73-128

    4. Mode of Action of Sulfonylureas

      • U. Panten, M. Schwanstecher, C. Schwanstecher
      Pages 129-159

    5. Sulfonylureas: Pharmacokinetics in Animal Experiments

      • A. Hasselblatt
      Pages 161-183

    6. Toxicology of Sulfonylureas

      • F. Hartig, K. H. Langer, W. Rebel, F. H. Schmidt, E. Schütz
      Pages 185-198

    7. Clinical Pharmacology of Sulfonylureas

      • L. Groop, G. Neugebauer
      Pages 199-259

  6. Biguanides

    1. Front Matter

      Pages 261-261
      Download chapter PDF

    2. Chemistry and Structure-Activity Relationships of Biguanides

      • E. Prugnard, M. Noel
      Pages 263-285

    3. Physicochemical Properties and Analytical Methods of Determination of Biguanides

      • E. Prugnard, M. Noel
      Pages 287-304

    4. Preclinical Pharmacology of Biguanides

      • N. F. Wiernsperger
      Pages 305-358

    5. Toxicology of Biguanides

      • F. Schmidt, F. Hartig, W. Rebel, P. Ochlich
      Pages 359-371

    6. Clinical Pharmacology of Biguanides

      • L. S. Hermann
      Pages 373-407

  7. Glucosidase Inhibitors

    1. Front Matter

      Pages 409-409
      Download chapter PDF

    2. Chemistry and Structure-Activity Relationships of Glucosidase Inhibitors

      • B. Junge, M. Matzke, J. Stoltefuss
      Pages 411-482

    3. Analytical Methods of Determination of Glucosidase Inhibitors

      • H. J. Ploschke, H. Schlecker, S. Seip, C. Wünsche
      Pages 483-496
Back to top

Keywords

About this book

The prevalence of diabetes continues to increase worldwide. Traditionally, diabetes in its adult form has not been considered a serious life-threatening disease. This attitude needs to be changed because the complications asso­ ciated with the adult form of diabetes affect almost every organ system. The high morbidity and mortality of non-insulin-dependent diabetes mellitus (NIDDM) suggest that current treatment strategies are unsatisfactory. We therefore face an urgent need for new therapeutic approaches. When the first Handbook 0/ Oral Antidiabetics was edited by H. Maske in 1971, the risks and benefits associated with the use of oral antidiabetics were still under discussion. Nowadays, oral antidiabetics hold a strong posi­ tion in the long-term treatment of diabetes. Roughly 30% -50% of the patients with diabetes in Europe and the United States are treated with oral antidiabetics, chiefly sulfonylureas. While acknowledging the value of the ß­ cytotropic sulfonylureas, we also need to recognize important limitations of their use, e.g., in the treatment of obese diabetic patients.

Editors and Affiliations

  • Institut für Klinische Pharmakologie, Bayer AG, Wuppertal, Germany

    Jochen Kuhlmann

  • Wuppertal, Germany

    Walter Puls

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation